Routine Use of Impella Reduces All-Cause Mortality at 180 Days in AMI Cardiogenic Shock due to STEMI Compared to Standard Care Alone (IMAGE)

Abiomed

Routine Use of Impella Reduces All-Cause Mortality at 180 Days in AMI Cardiogenic Shock due to STEMI Compared to Standard Care Alone

Caption

Routine Use of Impella Reduces All-Cause Mortality at 180 Days in AMI Cardiogenic Shock due to STEMI Compared to Standard Care Alone

Credit

Courtesy of Abiomed

Usage Restrictions

No restrictions

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.